AbbVie Inc. (ABBV)
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
U.S. politicians dump this pharma stock days before Trump's drug price order
Summary ⚈ Two U.S. lawmakers sold AbbVie shares shortly before Trump's drug price-cutting announcement, raising concerns about potential insider knowledge. ⚈ Trump's May 13 executive order targets up to 80% reductions in drug costs, directly impacting companies like AbbVie.
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those that don't rely too heavily on international markets.
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why AbbVie Stock Trounced the Market Today
The positive, post-earnings momentum lifting AbbVie's (ABBV 3.57%) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session.
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report
Major U.S. equities indexes were mixed on the first day of a new trading week that will feature earnings reports from a slew of major corporations.
Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq.
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises. So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Why AbbVie Stock Topped the Market Today
A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (ABBV 3.10%) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 index it's a part of.
